Comparative studies on the cytochrome p450-associated metabolism and interaction potential of selegiline between human liver-derived in vitro systems.

Selegiline was used as a model compound in a project aimed at comparing, evaluating, and integrating different in vitro approaches for the prediction of cytochrome p450 (p450)-catalyzed hepatic drug metabolism in humans (EUROCYP). Metabolic predictions were generated using homology modeling, cDNA-expressed p450 enzymes, human liver microsomes, primary cultured human hepatocytes, and precision-cut human liver slices. All of the in vitro systems correctly indicated the formation of two dealkylated metabolites, desmethylselegiline and methamphetamine. The metabolic instability of selegiline was demonstrated by all of the in vitro systems studied. Estimates of clearance varied from 16 l/h to 223 l/h. With the exception of one approach, all systems underpredicted the in vivo clearance in humans (236 l/h). Despite this, all approaches successfully classified selegiline as a high clearance compound. Homology modeling suggested the participation of CYP2B6 in the demethylation of selegiline and of CYP2D6 in the depropargylation of the drug. Studies with recombinant expressed enzymes and with human hepatic microsomal fraction supported the involvement of CYP2B6 but not of CYP2D6. These techniques also suggested the involvement of CYP1A2, CYP2C8, and CYP2C19 in the biotransformation of selegiline. In vitro, CYP2B6 was the most active form of p450 involved in selegiline metabolism. Metabolism by several enzymes operating in parallel implies a low interaction potential for the drug. None of the techniques alone was able to predict all aspects of the metabolic and kinetic behavior of selegiline in vivo. However, when used as an integrated package, all significant characteristics were predictable.

[1]  M. Anttila,et al.  Selegiline metabolism and cytochrome P450 enzymes: in vitro study in human liver microsomes. , 2008, Pharmacology & toxicology.

[2]  R. Tyndale,et al.  Inhibition of cytochromes P450 by antifungal imidazole derivatives. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[3]  M. Ingelman-Sundberg,et al.  CYP2B6 and CYP2C19 as the major enzymes responsible for the metabolism of selegiline, a drug used in the treatment of Parkinson's disease, as revealed from experiments with recombinant enzymes. , 2001, Drug metabolism and disposition: the biological fate of chemicals.

[4]  U. Hofmann,et al.  Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver. , 2001, Pharmacogenetics.

[5]  R J Edwards,et al.  An assessment of human liver-derived in vitro systems to predict the in vivo metabolism and clearance of almokalant. , 2001, Drug metabolism and disposition: the biological fate of chemicals.

[6]  L. Bertilsson,et al.  CYP2C19 polymorphism is not important for the in vivo metabolism of selegiline , 2001, European Journal of Clinical Pharmacology.

[7]  L. Corcos,et al.  Carbamazepine: a 'blind' assessment of CYP-associated metabolism and interactions in human liver-derived in vitro systems , 2001, Xenobiotica; the fate of foreign compounds in biological systems.

[8]  C. Lindley,et al.  Validation of bupropion hydroxylation as a selective marker of human cytochrome P450 2B6 catalytic activity. , 2000, Drug metabolism and disposition: the biological fate of chemicals.

[9]  D. Greenblatt,et al.  CYP2B6 mediates the in vitro hydroxylation of bupropion: potential drug interactions with other antidepressants. , 2000, Drug metabolism and disposition: the biological fate of chemicals.

[10]  G. Baker,et al.  Metabolism of N,N-dialkylated amphetamines, including deprenyl, by CYP2D6 expressed in a human cell line , 2000, Xenobiotica; the fate of foreign compounds in biological systems.

[11]  S. Ekins,et al.  The role of CYP2B6 in human xenobiotic metabolism. , 1999, Drug metabolism reviews.

[12]  P. Beaune,et al.  Human CYP2B6: expression, inducibility and catalytic activities. , 1999, Pharmacogenetics.

[13]  J B Houston,et al.  Kinetics of drug metabolism in rat liver slices: IV. Comparison of ethoxycoumarin clearance by liver slices, isolated hepatocytes, and hepatic microsomes from rats pretreated with known modifiers of cytochrome P-450 activity. , 1999, Drug metabolism and disposition: the biological fate of chemicals.

[14]  R. Huupponen,et al.  Dose linearity study of selegiline pharmacokinetics after oral administration: evidence for strong drug interaction with female sex steroids. , 1999, British journal of clinical pharmacology.

[15]  L. Bertilsson,et al.  CYP2D6 polymorphism is not crucial for the disposition of selegiline , 1998, Clinical pharmacology and therapeutics.

[16]  S. Ekins,et al.  Further characterization of the expression in liver and catalytic activity of CYP2B6. , 1998, The Journal of pharmacology and experimental therapeutics.

[17]  R. Edwards,et al.  Development of a comprehensive panel of antibodies against the major xenobiotic metabolising forms of cytochrome P450 in humans. , 1998, Biochemical pharmacology.

[18]  Rodrigues Ad,et al.  Preclinical drug metabolism in the age of high-throughput screening: an industrial perspective. , 1997 .

[19]  D J Rance,et al.  The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. , 1997, The Journal of pharmacology and experimental therapeutics.

[20]  J B Houston,et al.  Scaling factors to relate drug metabolic clearance in hepatic microsomes, isolated hepatocytes, and the intact liver: studies with induced livers involving diazepam. , 1997, Drug metabolism and disposition: the biological fate of chemicals.

[21]  H. Shin,et al.  Metabolism of selegiline in humans. Identification, excretion, and stereochemistry of urine metabolites. , 1997, Drug metabolism and disposition: the biological fate of chemicals.

[22]  J. Houston,et al.  Kinetics of drug metabolism in rat liver slices. III. Relationship between metabolic clearance and slice uptake rate. , 1997, Drug metabolism and disposition: the biological fate of chemicals.

[23]  T. Poulos,et al.  The structure of the cytochrome p450BM-3 haem domain complexed with the fatty acid substrate, palmitoleic acid , 1997, Nature Structural Biology.

[24]  C. Olanow,et al.  l‐Deprenyl Protects Mesencephalic Dopamine Neurons from Glutamate Receptor‐Mediated Toxicity In Vitro , 1997, Journal of neurochemistry.

[25]  W. Koller.  Selegiline monotherapy in the treatment of Parkinson's disease , 1996, Neurology.

[26]  K. Sotaniemi,et al.  Role of selegiline in combination therapy of Parkinson's disease , 1996, Neurology.

[27]  G. Shenfield,et al.  The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. , 1996, Pharmacogenetics.

[28]  M. T. Donato,et al.  Effect of model inducers on cytochrome P450 activities of human hepatocytes in primary culture. , 1995, Drug metabolism and disposition: the biological fate of chemicals.

[29]  J. Houston,et al.  Kinetics of drug metabolism in rat liver slices. Rates of oxidation of ethoxycoumarin and tolbutamide, examples of high- and low-clearance compounds. , 1995, Drug metabolism and disposition: the biological fate of chemicals.

[30]  M. Kinter,et al.  Atypical metabolism of deprenyl and its enantiomer, (S)-(+)-N,alpha-dimethyl-N-propynylphenethylamine, by cytochrome P450 2D6. , 1994, Chemical research in toxicology.

[31]  L. Corcos,et al.  Cytokines down-regulate expression of major cytochrome P-450 enzymes in adult human hepatocytes in primary culture. , 1993, Molecular pharmacology.

[32]  S. Wrighton,et al.  Isolation and characterization of human liver cytochrome P450 2C19: correlation between 2C19 and S-mephenytoin 4'-hydroxylation. , 1993, Archives of biochemistry and biophysics.

[33]  J Deisenhofer,et al.  Crystal structure of hemoprotein domain of P450BM-3, a prototype for microsomal P450's. , 1993, Science.

[34]  Tim Morris,et al.  Physiological Parameters in Laboratory Animals and Humans , 1993, Pharmaceutical Research.

[35]  R. J. Price,et al.  Culture of precision-cut liver slices: effect of some peroxisome proliferators. , 1993, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[36]  M. Brin,et al.  Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. , 1993, The New England journal of medicine.

[37]  L. Azároff,et al.  Phenobarbital induction of cytochrome P-450 gene expression. , 1992, The Biochemical journal.

[38]  W. Tatton,et al.  Rescue of dying neurons: A new action for deprenyl in MPTP parkinsonism , 1991, Journal of neuroscience research.

[39]  T. Aoyama,et al.  Steroid hormone hydroxylase specificities of eleven cDNA-expressed human cytochrome P450s. , 1991, Archives of biochemistry and biophysics.

[40]  P. Beaune,et al.  Hydroxylation of chlorzoxazone as a specific probe for human liver cytochrome P-450IIE1. , 1991, Chemical research in toxicology.

[41]  M. Bayliss,et al.  Prediction of intrinsic clearance of loxtidine from kinetic studies in rat, dog and human hepatocytes. , 1990, Biochemical Society transactions.

[42]  M. Ståhlberg,et al.  Immunochemical detection of human liver cytochrome P450 forms related to phenobarbital-inducible forms in the mouse. , 1990, Biochemical pharmacology.

[43]  A. Boobis,et al.  Furafylline is a potent and selective inhibitor of cytochrome P450IA2 in man. , 1990, British journal of clinical pharmacology.

[44]  V. Myllylä,et al.  Pharmacokinetics and metabolism of selegiline. , 1989, Acta neurologica Scandinavica. Supplementum.

[45]  J. Gaál,et al.  Effect of MAO inhibitors on the uptake and metabolism of dopamine in rat and human brain. , 1988, Polish journal of pharmacology and pharmacy.

[46]  M. Lang,et al.  Immunochemical and catalytical studies on hepatic coumarin 7-hydroxylase in man, rat, and mouse. , 1988, Biochemical pharmacology.

[47]  F. Guengerich,et al.  Hepatic metabolism of tolbutamide: characterization of the form of cytochrome P-450 involved in methyl hydroxylation and relationship to in vivo disposition. , 1987, The Journal of pharmacology and experimental therapeutics.

[48]  T. Kronbach,et al.  High-performance liquid chromatographic assays for bufuralol 1'-hydroxylase, debrisoquine 4-hydroxylase, and dextromethorphan O-demethylase in microsomes and purified cytochrome P-450 isozymes of human liver. , 1987, Analytical biochemistry.

[49]  Takemi Yoshida,et al.  Metabolism of deprenyl, a selective monoamine oxidase (MAO) B inhibitor in rat: relationship of metabolism to MAO-B inhibitory potency. , 1986, Xenobiotica; the fate of foreign compounds in biological systems.

[50]  I. Oswald,et al.  MPTP parkinsonism. , 1984, British medical journal.

[51]  C. Walsh,et al.  Regioselectivity and stereoselectivity of androgen hydroxylations catalyzed by cytochrome P-450 isozymes purified from phenobarbital-induced rat liver. , 1983, The Journal of biological chemistry.

[52]  L. Oreland,et al.  The acetylenic monoamine oxidase inhibitors clorgyline, deprenyl, pargyline and J‐508: their properties and applications , 1981, The Journal of pharmacy and pharmacology.

[53]  G. Reynolds,et al.  Deprenyl is metabolized to methamphetamine and amphetamine in man. , 1978, British journal of clinical pharmacology.

[54]  A. Aitio.  A simple and sensitive assay of 7-ethoxycoumarin deethylation. , 1978, Analytical biochemistry.

[55]  M. M. Bradford.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. , 1976, Analytical biochemistry.

[56]  Grant R. Wilkinson,et al.  A physiological approach to hepatic drug clearance , 1975 .

[57]  Oliver H. Lowry,et al.  Protein measurement with the Folin phenol reagent. , 1951, The Journal of biological chemistry.

[58]  A. D. Rodrigues.  Preclinical Drug Metabolism in the Age of High-Throughput Screening: An Industrial Perspective , 2004, Pharmaceutical Research.

[59]  Honglu Zhang,et al.  A method for the simultaneous evaluation of the activities of seven major human drug-metabolizing cytochrome P450s using an in vitro cocktail of probe substrates and fast gradient liquid chromatography tandem mass spectrometry. , 2001, Drug metabolism and disposition: the biological fate of chemicals.

[60]  D. Lewis,et al.  Cytochrome P450 Substrate Specificities, Substrate Structural Templates and Enzyme Active Site Geometries , 1999, Drug metabolism and drug interactions.

[61]  J. Tredger,et al.  3,3'-Diindolylmethane induces CYP1A2 in cultured precision-cut human liver slices. , 1998, Xenobiotica; the fate of foreign compounds in biological systems.

[62]  Y. Sugiyama,et al.  Quantitative prediction of in vivo drug clearance and drug interactions from in vitro data on metabolism, together with binding and transport. , 1998, Annual review of pharmacology and toxicology.

[63]  A. Boobis,et al.  Interlaboratory comparison of the assessment of P450 activities in human hepatic microsomal samples. , 1998, Xenobiotica; the fate of foreign compounds in biological systems.

[64]  O Pelkonen,et al.  Inhibition and induction of human cytochrome P450 (CYP) enzymes. , 1998, Xenobiotica; the fate of foreign compounds in biological systems.

[65]  T Ishizaki,et al.  Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data. , 1997, Pharmacology & therapeutics.

[66]  J B Houston,et al.  Prediction of hepatic clearance from microsomes, hepatocytes, and liver slices. , 1997, Drug metabolism reviews.

[67]  M. Gómez-Lechón,et al.  6 – Isolation, Culture and Use of Human Hepatocytes in Drug Research , 1997 .

[68]  J. Castell,et al.  In vitro methods in pharmaceutical research , 1997 .

[69]  M. Caligiuri,et al.  Portable device for quantifying parkinsonian wrist rigidity , 1994, Movement disorders : official journal of the Movement Disorder Society.

[70]  M. Carrillo,et al.  (-) deprenyl induces activities of both superoxide dismutase and catalase but not of glutathione peroxidase in the striatum of young male rats. , 1991, Life sciences.

[71]  H Babich,et al.  Comparisons of two in vitro cytotoxicity assays-The neutral red (NR) and tetrazolium MTT tests. , 1988, Toxicology in vitro : an international journal published in association with BIBRA.

[72]  T. Yoshida,et al.  Hepatic and extrahepatic metabolism of deprenyl, a selective monoamine oxidase (MAO) B inhibitor, of amphetamines in rats: sex and strain differences. , 1987, Xenobiotica; the fate of foreign compounds in biological systems.

[73]  A. Guillouzo,et al.  Isolated and cultured hepatocytes , 1986 .

[74]  O. Hinsvark,et al.  Quantitative determination of dextromethorphan and three metabolites in urine by reverse-phase high-performance liquid chromatography. , 1984, Journal of pharmaceutical sciences.

[75]  G. Zsilla,et al.  The action of (-) deprenyl on monoamine turnover rate in rat brain. , 1982, Advances in biochemical psychopharmacology.

[76]  E. Costa,et al.  Typical and atypical antidepressants. Molecular mechanisms. , 1982, Advances in biochemical psychopharmacology.

[77]  R. Mayer,et al.  Characteristics of a microsomal cytochrome P-448-mediated reaction. Ethoxyresorufin O-de-ethylation. , 1977, Drug metabolism and disposition: the biological fate of chemicals.